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In vivo degeneration and the fate of
inorganic nanoparticles
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What happens to inorganic nanoparticles (NPs), such as plasmonic gold or silver, superparamagnetic iron
oxide, or fluorescent quantum dot NPs after they have been administrated to a living being? This review
discusses the integrity, biodistribution, and fate of NPs after in vivo administration. The hybrid nature of the
NPs is described, conceptually divided into the inorganic core, the engineered surface coating comprising of
the ligand shell and optionally also bio-conjugates, and the corona of adsorbed biological molecules. Empirical
evidence shows that all of these three compounds may degrade individually in vivo and can drastically modify
the life cycle and biodistribution of the whole heterostructure. Thus, the NPs may be decomposed into
different parts, whose biodistribution and fate would need to be analyzed individually. Multiple labeling and
quantification strategies for such a purpose will be discussed. All reviewed data indicate that NPs in vivo should
no longer be considered as homogeneous entities, but should be seen as inorganic/organic/biological nano-
hybrids with complex and intricately linked distribution and degradation pathways.
Nanoparticles as tunable tools towards
application in nanobiomedicine
The applications of engineered nanomaterials (NMs) are not only
increasing in technical products, but are also more and more
common in biotechnology and biomedicine.1–4 The intersection of
nanotechnology and biomedicine defines one of the most exciting
and cross-disciplinary developments over the last decade.1,2,4,5 NMs
and in particular, colloidal inorganic nanoparticles (NPs), are
increasingly considered as novel, promising tools with improved
therapeutic efficacy, biodistribution, and pharmacokinetics.3,6–9
Recent advancements in synthesis and the ability to rationally
manipulate NM and NP features, such as their physical, chemical,
and biological properties open up additional possibilities in design-
ing a new generation of nanoprobes for theranostic applications.10–18
For example, considerable progress in the development of
magnetic NPs with engineered physicochemistry and tailored
surfaces properties19 has opened up a variety of clinically
relevant applications, such as magnetic resonance imaging (MRI),
drug delivery, magnetic hyperthermia, and low cost in vitro
diagnostics.3,6,8,9,20–24 Also, plasmonic NPs, in particular Au
NPs, are used for similar purposes,25 ranging from plasmonic
sensing, photoacoustic imaging, drug delivery, photothermal
therapy (PTT), photodynamic therapy (PDT), and many others.26–29
Fluorescent semiconductor NPs, the so-called quantum dots
(QDs),30 have been proposed as contrast agents for fluorescence
imaging, guided surgery,31 PDT, etc., though their clinical in vivo
use is still under debate due to their potential toxicity. Moreover,
with the advent of the concept of so-called ‘personalized medicine’,
the field of nanobiomedicine has started to grow, producing a huge
variety of different multi-functional NMs. However, despite the
increasing production of new nano-tools, to date only a few of them
have reached the clinics.32 Yet, some formulations based on gold
and iron oxide NPs have already been approved or are in phase 3 of
clinical trials. One of the most challenging technical difficulties
that NMs are facing in biomedicine, is to successfully cross
biological barriers and specifically recognize their targets while
they circulate through the body5 (cf. Fig. 1). Moreover, the use of
NMs may pose unknown risks to patients, thus current enthusiasm
for nanotechnology might shift towards safer approaches.5,33–37 This
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review focuses on NMs and NPs designed for biomedical applica-
tion. However, as these materials are also used in industrial and
technological sectors, from which they may be released into the
biological environment at a certain period of their life cycle, the
arguments on degradation of NPs given below also apply to materi-
als involved in non-intentional exposure of living organisms.
Nanoparticles in the biological
environment transform into composites
What happens to NPs once they have been administered
in vivo? Though the in vivo biodistribution of inorganic NPs
(e.g., plasmonic NPs, superparamagnetic NPs, and quantum dots)
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Schumacher at the University Medical Center Hamburg-Eppendorf (UKE). Since 2013, he is Postdoc in the group of Prof. Jörg Heeren at the UKE. His
research interest is focused on the regulation of triglyceride-rich lipoprotein uptake in to adipose tissue and visualization of uptake processes with
nanoparticles using intravital microscopy and magnetic resonance imaging (MRI).
Pablo del Pino studied Physics at the Universidad de Sevilla, Spain and obtained his PhD degree from Technische Universität München, in 2007. He
has been a researcher at the Ludwig-Maximilians-Universität München (2007–2009), Institute of Nanoscience of Universidad de Zaragoza (2009–
2013) and CIC biomaGUNE (2013–2015). In 2015 he was awarded with a Ramon y Cajal grant. His current research interests focus on the
development of materials for applications in life science.
Sumaira Ashraf obtained her Masters degree in Chemistry from Institute of Chemistry, University of the Punjab, Lahore and her PhD (Nano-
biotechnology) from Quaid-i-Azam University Islamabad and in the Biophotonics group, Philipps University of Marburg. She joined Pakistan Institute
of Engineering and Applied Sciences (PIEAS) as Assistant Professor in 2013. Since then, she is a postdoctoral fellow supported by the Alexander von
Humboldt (AvH). Her research interest is focused on the synthesis and characterization of colloidal nano- and microparticles and their interaction with
cells.
Jelena Kolosnjaj-Tabi received her undergraduate degree in pharmacy from the University of Ljubljana, Slovenia and earned her MSc and PhD in nano
toxicology form the University Paris 11. She is an awardee of the Chancellery of the Universities of Paris and spent four years as a postdoctoral fellow
at the Paris Cardiovascular Research Center (University Paris Descartes) and University Paris Diderot. Her main research interest concerns the
evaluation of the in vivo behavior of nanoparticles, their use for cell-based therapies and the application of nanomaterials for improving the therapy
and diagnosis of cancer.
Paolo Macchiarini obtained his Medical Degree in 1986 from the University of Pisa. He obtained his MSc and PhD degree in Organ and Tissue
Transplantation at the University of Franche-Cômpte. He became Chairman of the Department of General Thoracic and Vascular Surgery at the
Heidehaus Hospital at the Medical School Hannover. Since 2010, he is Director of the Advanced Center of Translational Regenerative Medicine
(ACTREM) at Karolinska Institutet, Stockholm, Sweden.
Peter Nielsen obtained his PhD in Organic Chemistry and Biochemistry and his MD at the Technische Universität München. He is currently an
assistant professor and group leader at the Department of Biochemistry and Molecular Biology at the University Medical Centre Hamburg-Eppendorf.
He works also as physician in a special ambulance on diseases of iron metabolism. His research interest spans across metabolism of iron and other
trace elements and is focussed in the last year on the synthesis of radiolabelled nanoparticles and their biodistribution and degradation in animal
models.
Damien Alloyeau obtained his PhD thesis on the thermodynamic properties of magnetic nanoalloys performed at the French Aerospace Lab (ONERA).
He was postdoctoral fellow at the Lawrence Berkeley National Laboratory. He joined the Materials and Quantum Phenomena laboratory at the
National Research Center for Scientific Research (CNRS) as a permanent researcher in 2010. He is a CNRS scientist at the Paris Diderot University. His
research interests focus on the fabrication of nanostructured materials, and to explore the life cycle of nanostructures in their application media.
Transmission electron microscopy still serve as a cornerstone of his researches.
Florence Gazeau obtained her PhD from the University Paris 7-Diderot, in 1997, focusing on the magnetic and hydrodynamic properties of ferrofluids.
She joined the National Research Center for Scientific Research (CNRS) as a staff scientist in 1998, when she broadened her research on biomedical
applications of magnetic nanoparticles. Her current research interests focus on the physics of nanomagnetism applied to nanomedicine, cell–
nanoparticles interactions, cellular MRI, nanoparticles-mediated hyperthermia, magnetic targeting, nanoparticles behavior in vivo and
nanotoxicology. She is a senior CNRS scientist since 2009, and she works in the laboratory MSC at the University Paris Diderot.


































































































2442 | Chem. Soc. Rev., 2016, 45, 2440--2457 This journal is©The Royal Society of Chemistry 2016
is relatively well investigated, the appraisal mainly concerns the
inorganic NP cores. However, the plain inorganic cores would not
be stable in biological environments. Without an organic surface
coating, either obtained by the chemical design or due to adsorbed
proteins, the NPs would agglomerate. Thus, NPs within the in vivo
environment are complex hybrids with an inorganic core and an
organic/biologic surface coating,38,39 cf. Fig. 2. Conceptually, we will
describe each NP as a hybrid object composed of three different
entities: the inorganic core, the engineered surface coating, and
compounds adsorbed from the biological environment.
The NP core defines the ‘‘physical identity’’ or, in other words, the
basic functional physical properties of NPs, such as being plasmonic,
superparamagnetic, or fluorescent.40 In this way, the core may
provide the contrast for several imaging/detection modalities or
create heat upon excitation for hyperthermia treatment, etc. The
persistence of the physical properties of the core in biological
environment is critical for theranostic efficiency of NPs. How-
ever, biotransformation of the NPs (aggregation, dissolution,
and degradation) might jeopardize such properties over time,
depending on the NP environment.
The engineered surface coating determines the intrinsic
physico-chemical properties of the NPs, sometimes also termed
‘‘synthetic identity’’.41 Typical surface coatings for inorganic
NPs involve short ligand molecules such as lipoic acid42,43 or
peptides,44 silica shells,45,46 polymer micelles,47 or lipid micelles.48,49
The resulting intrinsic physico-chemical properties, such as surface
charge, hydrophilicity/hydrophobicity, etc., play an important role in
the colloidal stability of the NPs. Appropriate surface coatings
prevent NPs from agglomeration and ensure dispersion of the NPs
in complex environments. The coatings also determine how the NPs
interact with biological environments, i.e., how molecules from these
environments adsorb to the NP surface. Distinct surface coatings
were shown to have a profound impact on the biocompatibility and
fate of NPs, including cell viability or cell adhesion, their cellular
uptake, lifetime in the blood system, and the biopersistence in
tissues belonging to the mononuclear phagocyte system (MPS;
formerly referred to as the reticuloendothelial system, RES).50–56
In addition, coatings may involve functionalization via conjugation
with targeting ligands and/or bioactive molecules for obtaining
multifunctional ‘intelligent’ NPs.57 In this way, the engineered
coating plays an important role in active targeting schemes.
It is often neglected that in complex physiological environ-
ments, such as blood, a certain degree of in situ biotransforma-
tion will most likely occur for all NPs. For the majority of in vivo
applications, NPs will be intravenously injected and immediately
exposed to a highly complex biological environment. There, a
plethora of ions58,59 and biomolecules, such as lipids, metabolites,
sugars, and especially proteins,60 will adsorb onto the surface of
the NPs, mediated by van der Waals, electrostatic, hydrogen
bonding, and hydrophilic/hydrophobic interactions.38,61–66 The
sum of all adsorption processes will result in the formation of
the so-called ‘biomolecule corona’, of which, so far, the protein
corona (PC) has mostly been studied. It is now accepted, but far
from being understood in detail, that the formation of a protein/
biomolecule corona critically affects not only the physico-chemical
characteristics of NPs,67 but also the (patho-) physiological and
biomedical identity, often simply referred to as ‘‘biological
identity’’41,68 of NPs in general.5,69–71 Hence, the properties of
corona-covered NPs differ (in most cases significantly) from the
intrinsic physico-chemical properties of the NPs, before their
exposure to biological environments.5,33,64,71 In the area of
corona research, the term ‘hard corona’ was coined to define
a protein adsorption signature of a NP, but is sometimes also
used to describe the ‘long-lived’ equilibrium protein signature
of a NP, e.g., the plasma protein signature of a NP in the
blood.4,62,64,71–73 On top of this ‘hard corona’, some models
also suggested the existence of a ‘soft corona’, which can be
conceptualized as a putative, loosely associated, and rapidly
transient layer of biomolecules.62,72,74–78 However, since such a
‘soft corona’ seems to desorb during current purification
processes, its existence, (patho)biological, and medical relevance
still remain vague.3,5 Here, a standardized definition would be very
helpful. In the following, only the analytically accessible proteins
associated as NP–protein complexes will be referred to as ‘protein
corona’ (PC). Notably, the PC not only (co)defines interaction
interfaces between NPs and biological environments, but may also
additionally trigger the NP transformation by altering their colloidal
stability. The PC can either have a stabilizing effect by inducing
steric stabilization or have a destabilizing impact caused by protein
mediated bridging, charge compensation and/or introduction
of charge inhomogeneity onto the NP surface.63,79–82 Upon
aggregation, multiple interactions may result in stronger affinities
compared to proteins binding to single NPs, which is likely to occur
in a biological solution, in which NPs are highly diluted. Moreover,
there could even be a trapping of proteins in such aggregates, with
otherwise low or no affinity for single NPs. Depending on the type
of NP, such aggregation may also require a certain time, and may
thus additionally impact the evolution of the PC.79–82 As protein
adsorption is a dynamic process depending on the affinity of
individual components for each other, it also varies with the
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ratio of NPs over available proteins. An important consequence
is that the PC differs in a medium with 10% serum, which is
currently used in cell culture in vitro, in comparison to in vivo
conditions under which the protein ratio is much higher.68
Taking together the statements from the last paragraphs, NPs
should be seen as complex hybrids formed via their interaction
with biological environments. The interplay between molecular
constituents of the biological medium in which the NPs are
dispersed and the synthetic NP surface determines the surface
properties of the NPs and their colloidal stability. Being colloids,
the ‘‘synthetic identity’’41 of NPs as well as their physical properties
need to be characterized in solution (ad minima in water), which
defines their surface charge, hydrophilicity/hydrophobicity, and
aggregation state. In the next step, the ‘‘biological identity’’41,68
also involves molecules from the biological medium which adsorb
to the NP surface. In this way, for a full characterization, NPs
dispersed in the actual biological medium are required. The final
step of characterization is to follow the processing of NPs within
an in vivo system.
Application routes and biodistribution
of nanoparticles
Upon administration, NPs will interact with cells. It is well
recognized from cell-culture studies that almost all mammalian
cells can, in principle, incorporate NPs to some extent, due to a
variety of non-specific uptake mechanisms.83 Many studies
have explored the NP properties which influence the efficiency
of cell uptake and also determine their intracellular processing,
resulting in complete or partial degradation, or storage of
biopersistent NPs in unchanged form in cells.84 However,
how relevant are these in vitro studies for the in vivo situation?
Mammalian cells can clearly process and degrade larger molecules
and NPs. Yet, this is not routinely necessary for all cells. Cells in
culture are also either dividing rapidly (cancer lines) or are
restricted in their metabolism (primary culture) and interactions.
Contrariwise, a close interaction between tissues exists in vivo, in
which certain cell types, such as the professional macrophages in
the mononuclear phagocyte system (MPS), are very potent in fast
clearance and processing of larger NPs from the blood flow,
whereas other cells may be very limited in their capacity to uptake
and process NPs. Importantly, in vivo, the NP clearance directly
depends on the global status of the immune system.85 This
implicates that, besides the physico-chemical properties of the
individual NP, the cell type, which is primarily exposed to the NPs,
and the model system used, will also influence the biodistribution,
intracellular transfer, and degradation of NPs in vivo.
Bolus injection into a peripheral vein seems to be the most
recurrent application route for most nanomedical applications.
Following intravenous (i.v.) injection, the blood flow would
spread the NPs into the right heart, through the lung capillaries,
back to the left heart and then into the arterial system supplying
each organ with the respective NPs. Under these conditions, a
main blood fraction will enter the liver and spleen, which have a
huge capacity to remove xenobiotic NPs from the blood stream.
A few studies have quantified the distribution of labeled
NPs,86,87 and it can be expected that a large fraction of most
protein-covered NPs will be taken up by these organs within
minutes after injection (cf. Fig. 3). Another cell type, involved in
the efficient uptake of NPs in vivo are endothelial cells, which
line veins, arteries, and capillaries throughout the body, and
Fig. 1 The in vivo pathway and fate of NPs through the human body.
While accidental exposure of humans to NPs and their entry into the body
most likely occur through inhalation and the oral route, biomedical
applications mainly focus on intravenous injection or oral application
routes. Upon inhalation, ingestion, or injection of pristine NPs, they come
into contact with various complex physiological environments, leading to
the covering of NPs with various biomolecules. Upon the formation of
such a corona made of biomolecules, the in vivo transformation of pristine
NPs is rapidly initiated. During their passage through different compartments of
the body, the in vivo degeneration and fate of NPs differ significantly, which is
indicated by the different symbols for the NPs. While NP–biomolecule corona
complexes are quite stable in plasma, their uptake into organs, such as the liver
can trigger corona and NP degradation. Likewise, the conditions in the
digestive tract, such as low pH and the presence of surfactants, may lead to
similar degradation processes. Such in vivo transformation of nanomaterials
should be considered in nanotoxicology and nanomedicine.
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thus come in direct contact with the injected NPs.4 Evidence
indicates that there could be a difference between endothelia in
the liver (liver sinus endothelial cells (LSECs) and peripheral
endothelial cells (PECs)), which differentially uptake NPs with
respect to their surface charge, with anionic NPs taken up by the
liver4,80,88,89 and cationic NPs preferentially binding to PECs.90
The situation is different after injection of NPs into the
peritoneal cavity or directly into a tumoral lesion,91 which is
Fig. 3 Distribution and degradation of intravenously injected 59Fe-labeled FeOx NPs in mice. The FeOx NPs consisted of a monodisperse iron oxide core
(11 nm diameter) coated with an amphiphilic polymer, poly(maleic anhydride-alt-1-octadecene), resulting in 25 nm negatively charged NPs in aqueous
solution. A large fraction of the NPs is taken up within minutes by liver cells (Kupffer cells and liver sinusoidal endothelial cells (LSECs)). The degradation of
the FeOx core of the NPs can be monitored and quantified by measuring the amount of
59Fe incorporated into the hemoglobin of newly formed
erythrocytes. The FeOx NPs are also incorporated in peripheral vascular endothelial cells (PVECs), which represent a large surface area in veins and
capillaries. Differences in the degradation efficiency among different cells indicate that FeOx NPs or NP remnants might remain in some cells, and thus
elicit a cell-specific chronic toxicity, which is hard to measure in vivo by standard toxicity tests. MPS = mononuclear phagocyte system (mainly liver and
spleen). The figure represents a compilation of images from several publications.80,86,88,89
Fig. 2 A typical inorganic NP within an in vivo environment comprises of an inorganic core (drawn in black), a capping organic surface, which provides
colloidal stability (drawn in grey) and a shell of adsorbed proteins (drawn in blue). The NPs can change their physicochemical properties under in vivo
conditions. This may involve dynamic exchange of the protein corona, depending on the variations in the biological environment and/or the activity of
‘‘cellular degradation machineries’’. Degradation may decompose the NPs into individual parts. Depending on the NP core material, the inorganic core
may start to decompose, and thereby change their physical and morphological properties. The organic coating around the inorganic NP core could also
be partly removed, as adsorbed proteins may be digested. A possible dissolution of the NP core is not depicted in the sketch.
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also relevant for nanomedicines.92 From the peritoneal cavity,
the NPs have to pass the visceral peritoneum first, a monolayer
of mesothelial cells, and then enter the interstitium, with its
lymph or blood vessels, which can transport them into the
blood pool. Likewise, pulmonary,93 dermal,94 and oral uptake
routes95,96 also have to be taken into account, in particular in
the case of environmental NP exposure due to air pollution or
spills. Very little quantitative information is available so far on
cell processing efficiency after in vivo administration through
abovementioned routes. Lademann et al. investigated the
NP–skin interactions for silica, titanium dioxide and silver
NPs. The vast amount of topically applied solid NPs stays on
the skin surface, deeper penetration of single NPs was seen by
X-ray microscopy, Raman spectroscopy and flow cytometric
studies, with hair follicles representing an important storage
and putative entry site.97,98 Kreyling et al. found that inert gold
NPs, administered intratracheally are phagocytosed mainly by lung
macrophages and only a tiny fraction of gold NPs translocated into
systemic circulation.99,100 Enterocytes in the gastrointestinal tract
seem to represent an effective barrier against NP uptake. So far,
experiments with gold NPs,95 carboxylate-functionalized poly-
styrene NPs,101 and iron oxide NPs88 have been performed to
elucidate the oral application route. Bargheer et al. studied the
intestinal absorption of iron from 59Fe or 51Cr-labeled cores of
FeOx NPs. After oral application of labelled NPs in mice, a
significant absorption of 59Fe but not of 51Cr was observed by
sensitive whole-body-counting. As ionic Cr3+ is known to be
almost not absorbed in rodents, the results show a partial
degradation of the iron oxide cores in the acidic stomach,
followed by the physiological absorption or released ionic
Fe2+, and almost exclude a relevant intestinal absorption of
intact NPs. It should be emphasized that we know far too little
about the accurate distribution of a given NP composite in vivo
and reliable techniques are urgently needed to document which
cells take up the respective NPs and to what extent.
Biological environments may impose
hostile conditions to nanoparticles
As outlined in the case of intended or accidental in vivo exposure,
NPs take a complex route through the body. From administration
until eventual intracellular long-term deposition or alternatively
excretion, the NPs are exposed to a variety of different biological
environments. The hostile conditions in those environments can
vary significantly, for example in pH or local protein (i.e., enzyme)
species composition, etc. Highly acidic compartments can be either
found at the organ level, inside the stomach or tumors, or at the
cell organelle level, in endosomes/lysosomes. Low pH and protein
adsorption can affect colloidal stability and favor NP aggregation
inducing detrimental modifications of their magnetic or optical
properties, when the NPs are clustered inside intra-cellular
compartments.102–104 Acidic media also facilitate the corrosion
of inorganic NP cores,105 such as in the case of plasmonic Ag
NPs,106–108 superparamagnetic FeOx NPs,
109,110 or fluorescent CdSe
NPs.111 Silica NPs can be, for example, completely dissolved
by hydrolysis.112 Enzymes and reactive oxygen species on the
other hand have been demonstrated, to be able under certain
conditions, to digest carbonic parts of NPs, as demonstrated for
example for carbonic, purely inorganic carbon nanotubes
(CNTs),113 the strongest and stiffest materials in terms of tensile
strength and elastic modulus.114 Thus, it is likely that enzymes can
also digest parts of organic surface coatings around inorganic NPs.
Indeed, the first evidence has been reported.115–117 Enzymes may
also attack proteins adsorbed onto the NP surface,118 and the PC
has been demonstrated to dynamically evolve.119
Thus, an important question to be addressed is the in vivo
integrity of the NPs. Will the organic surface coating and the PC
of internalized NPs remain unmodified, or will they be (partly)
degraded in vivo? Continuing with this train of thought leads to
many potential implications. If the ligand shell of organic NPs
is degraded after internalization, how much can fancy surface
chemistries performed on NPs direct their biodistribution?
This would have an impact on the ongoing discussion of passive
versus active tumor targeting. Can organic surface coatings possibly
resist enzymatic degradation? On the contrary, while for some
applications NP degradation is unwanted, other applications might
require it. For example, can inorganic NPs be designed to be
degradable into fragments that can be cleared from the body by
renal excretion? An improved NP design could accordingly allow for
a new generation of inorganic NPs tailored for medical applications
with controlled degradability.
Since this kind of research is still in its infancy, this review
aims at providing an overview about what is already known
about the in vivo integrity of inorganic NPs and how their in vivo
physico-chemical and biomedical properties evolve. As in this
review NPs are considered as hybrids, including the inorganic
core, engineered surface coating, and adsorbed biological
molecules (cf. Fig. 2), the fate of all these compounds needs
to be investigated for a detailed analysis. The fate of a given
hybrid NP in vivo depends on various factors such as the
entrance route, PC formation in blood, distribution in the
cardiovascular system, etc., uptake into different cell types,
intracellular degradation and release, processing of the inorganic
core or organic materials, etc. Even if uniformity and full colloidal
stability of the NPs are provided during intravenous injection, it
cannot be expected that all NP components end up in the same
functional pool in vivo. Therefore, multiple labeling strategies are
needed by which the different components can be observed
independently.120 These would involve reliable quantification
techniques for the inorganic core material as well as for attached
organic molecules, in order to balance at least the main distribu-
tion paths for a given NP. Radioactive labeling is a historical
tool with great value to monitor the transport and metabolism
pathways of biomolecules. This technique has already been used
to trace the kinetics of Au,121 Cd, and Fe-based NPs in vivo.86 In
addition, MRI and fluorescence imaging can be used to record
biodistributions,87,122,123 but are incapable of detecting absolute
amounts as the fluorescence of molecules and magnetic resonance
relaxivities may depend on the local environment and aggregation
state of NPs. It is also of utmost importance to involve all the
controls which are necessary to prove that the labels are attached
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permanently to the respective NP compound.124,125 Detachment of
the label would lead to the determination of the biodistribution of
the free label, and not of the labeled NPs. In the following text, the
in vivo fate of the three different NP compounds, i.e. the core,
engineered coating, and adsorbed biomolecules will be discussed
individually. We will hereby start from the outside to the inner
parts of the NPs, i.e., from the PC to engineered organic coatings to
the inorganic core.
Degradation/evolution of the corona
of surface-adsorbed biomolecules
The first part of NPs, which is likely to interact with the environment,
is the PC, being the outermost entity. Having pointed out that the PC
clearly (co)defines the ‘‘biological identity’’41,68 and fate of NPs in
biological environments, it is clear that understanding its evolution
and exchange processes in vivo becomes crucial to produce nontoxic
and effective NPs.3,62,71,126 In vitro experiments have shown that the
formation of the PC influences cellular uptake of NPs, which appears
to be dependent on the nature of the adsorbed proteins.3,61,62,64,71,126
Elucidating the fate of the PC during the delivery of the NPs in vivo is
also a key determinant for developing efficient nanomedicines.3 The
complexity of the biological environment can strongly alter the
composition of PCs during their systemic route through the body
with possible biological implications (cf. Fig. 3). The specific fate of
NPs mostly depends on the entry or chosen administration route
(cf. Fig. 3). For example, an intravenously injected NP formulation
will incur the following biological processes: vascular transport,
extravasation, interstitial passage (extra-cellular matrix), cellular
uptake, and clearance. Thus, NPs and more realistically cognate
PCs will need to overcome different biological barriers before
reaching their final intended or unintended destination.
Numerous studies have shown that the physicochemical
properties of pristine NPs, such as size, shape, and surface
chemistry (termed the 3 ‘S’) can influence the amount, compo-
sition and in situ evolution of the PC, which in turn can
(co)determine the NP bioactivity.33,63,64,72,127–129 For example,
there is evidence that the PC is capable of regulating various
cell–NP interactions,64,126,130–132 blood residence time,133,134
(tumor) cell targeting activity and pharmacokinetic profiles,134
albeit the underlying molecular mechanisms are not yet
fully resolved. A variety of ex situ and some in situ studies have
been conducted to dissect and mechanistically understand
the biomolecule corona on the nanoscale, its dependence on
the physico-chemical properties of NPs and its impact on the
biotransformation and fate of NMs in the human body and
environmental systems.33,63,64,72,128,129,135 Typically, corona
profiles differ significantly from the protein composition of
the investigated (biological) fluid.62–64,82,126 Distinct proteins
will either enrich or display only weak affinity for the NP
surface. Despite significant work concerning the important
relationship between the original surface functionality of the
NPs and the nature of the corona, it currently still remains
impossible to predict or simulate these interactions in complex
physiological environments.5,63,64,72,126
Despite the complexity and analytical challenges already occur-
ring in ex situ characterization of the PC, additional challenges are
faced during its in situ analysis. In particular, when NPs move from
one physiological (micro)environment of the body to another, e.g.,
from the circulation via different cellular uptake mechanisms
into cells and different organs, such as the liver or spleen, a key
question is whether the original corona remains stable or is
subjected to substantial changes, which again adds an additional
level of complexity.62–64,71,72,86,92,105,125,126,129,136,137 So far, it is
assumed that even after passing through several ‘‘physiological
(micro)environments’’, the final corona would still contain a
fingerprint of its history and keep a memory of its prior passage
through the body,63,105,138 which is in line with recent reports
showing the stability of PC signatures ex situ.5,64
Though other studies suggest that PCs may be subject to
modifications in their composition while they reside in the
body, when they encounter different biological environments,
as it occurs for NPs conceived to target tumors.3,63,105,139,140
A study on silica NPs indicated that PCs formed in serum and
then transferred to cytosolic extracts experienced qualitative
changes in the composition. Yet, these results should be carefully
interpreted, as analytical methods may not detect low corona
protein concentrations.138
However, the majority of the studies conducted so far
demonstrated a stable PC fingerprint, originating from the
biological fluid the NPs encounter first, unless processing is
performed by enzymatic cellular machineries.63,125,138,141 Here,
dissolution processes have been recognized as being essential
for the fate, biodistribution and toxicity, particularly for metal
and metal oxide NPs.126,142–146 Even while investigating the
intracellular fate of silica-coated magnetite NPs by recovering
NP-containing cellular organelles, employing magnetic separation
techniques, studies demonstrated that PCs, associated with
NPs extracted from different cellular compartments, still
retained a cytoplasmic fingerprint, albeit additional proteins
adsorbed to the ‘‘precoated’’ NPs.147 Radioactive double-
labeling was a convenient analytical technique for investigating
the stability of a preformed protein corona in vivo. For example,
adsorbed 121I-labelled transferrin was transported efficiently
into the liver.80 Collectively, the conservation of specific protein
signatures in the PCs from different physiological compart-
ments encountered by the NPs may potentially allow recon-
structing the NP history through the body. The extent of
rearrangements/evolution in PC fingerprints are related to the
3 ‘S’ of NPs, and additional factors such as exposure time,64
temperature,148 and composition of the encountered physiological
environments. As the PC remains an unpredictable complex
factor, there are currently numerous attempts to chemically
prevent and/or modulate protein adsorption.62,63,134,149–151 Such
chemical strategies include hydrophilic oligomeric or polymeric
PEGylation152 and zwitterionic low molecular weight and poly-
meric coatings which reduce PC formation.
Again, there are many issues that are yet to be unraveled.
What role does enzymatic degradation play in addition to
composition exchange for the PC? In vitro experiments have
suggested that after intracellular incorporation, lysosomal enzymes
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may digest parts of the original PC.118 Advanced techniques are
required to detect the modifications occurring in situ. These
techniques would complement classical methods, which allow
detecting the composition of the PC, but require extractions
steps, which might be responsible for the formation of a new
equilibrium after each purification procedure, and might
significantly change the PC composition.153 Standard in situ
techniques, such as dynamic light scattering (DLS) and fluorescence
correlation spectroscopy (FCS), which can be conveniently applied to
PC characterization in sample solutions of biological liquids148,154,155
are unlikely to be suitable for in vivo analysis. Instead, spectroscopy
techniques in which the read-out signal depends on the adsorption
of proteins, such as surface enhanced Raman scattering (SERS), may
offer good possibilities.156–158
Degradation of engineered surface
coatings of nanoparticles
The engineered organic surface coating providing the ‘‘synthetic
identity’’41 of NPs lies beneath the PC. However, concerning the
in vivo stability of engineered surface coatings, there is not much
work reported in the literature. Clearly there is an indication that
in vitro, inside endosomes/lysosomes, part of the surface coating
may be released from the NP core. The endo/lysosomal enzyme
cathepsin L, for example, potentially cleaves a third of the
human proteome and the degradation of peptides conjugated
to the surface of NPs has been shown within endosomal
compartments.115 The enzyme a-glucosidase has also been
demonstrated to degrade the carboxydextran shell around the
NP core.116
Degradation has been shown quantitatively by using a double
labeling technique. A 14C-labeled peptide or a 125I-labeled protein
was covalently bound to 59Fe-labeled iron oxide cores, and the
radioactivity of the labels was followed in the blood and in ex vivo
samples of organs after two hours. From both NPs, no separation
between core and shell molecules was found while in blood
circulation (cf. Fig. 4). A covalently bound 11-As myelin basic protein
(MBP) was transported efficiently into LSECs, where the immune
competent peptide must have been separated from the core and was
presented on the surface of the cells, because the onset of experi-
mental autoimmune encephalomyelitis was completely prevented
in a mouse model of multiple sclerosis89 (cf. Fig. 4, upper lane).
Likewise, covalently bound or in vitro adsorbed 125I-labeled mouse-
transferrin was not separated from the 59Fe-label in blood and was
transported into the liver, where however, a complex metabolism
and re-distribution of this physiologically relevant plasma protein
occurred (cf. Fig. 4, lower lane).80,88
The use of radiolabeled NPs thus clearly provides a powerful
tool, especially for the sensitive and reliable quantification of
the distribution of the different parts of NPs. However, this
requires special equipment and the selection of appropriate
isotopes is critical. For each isotope, the individual transport
mechanisms must be carefully taken into account by including
a control group, in which an ionic probe of the element under
study is handled in the same way as the NPs.
In yet another study, partial separation of the engineered polymer
shell around the Au core was demonstrated.125 Here the polymer
Fig. 4 Fate of two double-labeled NPs in vivo. The upper lane displays polymer-coated 59Fe-labeled FeOx NPs. The carboxyl groups of the surface were
covalently coupled to a 14C-labeled peptide (11-As, myelin basic protein). After i.v. injection in groups of mice (n = 3–4), the 59Fe and 14C-labels
disappeared synchronously from blood following a first order kinetics due to the fast uptake mainly into liver and spleen.89 In the bottom lane, poly-
mer-coated 59Fe-labeled FeOx NPs were covalently labeled with
125I-labeled mouse-transferrin. The blood half-life and organ distribution were followed
in groups of mice after i.v. injection. Again, a synchronous removal of both labels from the blood was found, probably indicating the uptake of intact NPs
into the liver, without separation of the protein covered shell/polymer from the core already in the bloodstream.80


































































































2448 | Chem. Soc. Rev., 2016, 45, 2440--2457 This journal is©The Royal Society of Chemistry 2016
shell was labeled with 111In, and the Au NPs with 198Au via
neutron activation, cf. Fig. 5. After intravenous application to
rats, biodistributions of 111In and 198Au were recorded after one
hour and 24 hour retention. Controls ensured that the labels
were not lost and in fact corresponded to the locations of the
core and polymer shell. The data presented in Fig. 5 indicate
that in particular in urine, more polymer shells than NP cores
were found. Therefore, it was concluded that after intravenous
injection, the polymer coated Au NPs are cleared by the
immune system and are transported to the liver, where they
are endocytosed. While in this way the majority of the NPs
(comprising core and engineered polymer shell) are trapped in
the cells of the liver, this also initiates their degradation.
Proteases in the endosomes/lysosomes of the cells where the
NPs are located may start cleaving the polymer shell. In the
particular case, the polymer shell comprising peptide bonds
could be readily cut by proteases present in endosomes/
lysosomes. The liberated polymer fragments were small enough
to be exocytosed leading to final renal excretion.
While these findings offer a first indication that engineered
surface coatings can be degraded, there is not much quantita-
tive information to be found in the literature. It is clear that in
endosomes/lysosome enzymes exist, which can cleave organic
surface coatings. These involve proteases, designed to cut proteins
or polypeptides into peptide fragments, which can cut peptide
bonds (such as cathepsin L or trypsin), and enzymes, designed
to cut polysaccharides into saccharides (such as a-glucosidase),
which can cut sugar bonds. However, this does not exclude the
existence of engineered NP coatings, which could withstand
enzymatic degradation. In addition to intracellular enzymes,
degradation may occur in blood by esterases,159 which could,
for example, cut coatings containing ester bonds. In this way,
for each engineered NP coating one would need to take into
account which enzyme could degrade this coating, and what
the biodistribution of this enzyme is. Double labeling of the
core and shell and double detection schemes, such as correla-
tive microscopy (scanning electron microscopy/fluorescence
microscopy), will surely be a useful tool for the investigation
of particle and coating distribution.
Degradation of the inorganic
nanoparticle core
Ultimately, the inorganic core, as the innermost part of NPs
may also be degraded. Obviously the degradation of the inorganic
NP core will be highly dependent on the composition of the NP
material. While for example NPs made of Ag, ZnO, CdSe, and FeOx
are known to corrode, and thus release metal ions,105 other
materials such as NPs made from Au are typically considered to
be inert and thus stable against degradation. However, as will be
discussed in this section, such NPs can also undergo structural
alterations. This can be assumed from different points of view.
First, ligands such as thiols can strongly bind to the Au surface, and
under certain conditions, this may lead to pulling-out Au atoms via
the ligand from the Au surface.160,161 Thiols are available in cells, as
for example in glutathione, an antioxidant produced by the cells.
Thus, in principle, it is possible that Au NPs (very slowly) dissolve.
Second, Au NPs can be made with different shapes. The surface
A and volume V of a cubic NP with side lengths d are A = 6d2 and
V = d3, respectively, leading to a unity surface A* = 6 for a NP
with unity volume V* = 1. In contrast, for the NP sphere with
diameter d the surface and volume are A = 4p(d/2)2 = pd2 and
V = (4p/3)(d/2)3 = (p/6)d3, respectively, leading to a unity surface
A* E 4.8 for a NP with unity volume V* = 1. Thus, for the same
volume, a cubic NP has a significantly bigger surface than a
spherical NP. The most stable and energetically favorable
configuration is the one with the smallest surface and thus
NPs with spherical geometries. Thermodynamic laws might
therefore govern shape transitions of internalized NPs. In
addition, some crystal facets may be more stable than others,
stabilizing different shapes or favoring degradation on preferential
faces. Thus, even for ‘‘inert’’ materials such as Au, degradation or
crystalline reorganization might occur to some extent.
The case of superparamagnetic iron oxide (FeOx) NPs, which
are known to be chemically reactive is discussed. In order to
quantify the inorganic core of NPs and its degradation residues
over time in the body, elemental analysis such as inductively
coupled plasma mass spectrometry (ICP-MS) is often used. The
difficulty is however in distinguishing between the original NPs
and their products of degradation. For FeOx NPs, elemental
Fig. 5 (A) Au cores were coated with an amphiphilic polymer. Cores and
polymer shells were labelled with 198Au and 111In, respectively. The question
was whether in vivo the polymer shells would remain around the cores or
whether they would separate. (B) The ratio of radioactivities originating from
111In and 198Au is shown for different organs 24 hours after retention. In case
this ratio is higher than one, the polymer must have come off the NP cores.
A figure adopted from Kreyling et al.,125 GIT = gastrointestinal tract.
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analysis is inappropriate due to the high amount of endogenous
iron forms. However, FeOx can be quantified and distinguished
from endogenous iron and non-magnetic residues by following
their magnetic properties by nanomagnetism methods such as
electron paramagnetic resonance (EPR) and temperature-
dependent susceptibility measurements.110,162 These magnetic
characterizations give information about the biotransformation
of the superparamagnetic iron core at short and long terms.
Soon after engulfment of FeOx NPs by macrophages, their
intracellular confinement impacts their magnetic dynamics
due to impaired rotational and translational mobility as well
as magnetic interactions. The high local density of FeOx NPs in
lysosomes results on one hand in a decrease of magnetic
susceptibility and, on the other hand, in an increase of
the temperature of transition between superparamagnetic and
ferromagnetic regimes, affecting in turn the MRI relaxivity and
heating capacity of the FeOx NPs under alternating magnetic
fields.102–104 At longer terms the evolution of superparamagnetic
properties of NPs may reflect the degradation of their iron oxide
core.109,110,163 MRI provides a non-invasive means to detect the
distribution and integrity of FeOx NPs over time in the same
animal, although quantification remains challenging since MRI
relaxivity significantly depends on the local environment and
physical state of NPs. EPR was used to quantify the dissolution or
elimination of superparamagnetic iron oxide from liver and
spleen over one year after intravenous administration of FeOx
NPs at the relevant dose for MRI application (2.5 mg kg1 body
weight). This included 7–8 nm spherical FeOx NPs with a
hydrophilic glucose-derivative coating, proposed by Guerbet
et al. as contrast agents for MRI,110 20 nm FeOx nanocubes,
coated with polyethylene glycol (PEG),91,163 and 13 nm iron
oxide/5 nm gold dimer heterostructures, coated with an amphi-
philic polymer or PEG.50 As expected, the nature of the coating of
the FeOx NPs determined their initial uptake in the organs of the
mononuclear phagocyte system,50 the PEG-coated NPs being less
accumulated in spleen and liver than the NPs coated with the
amphiphilic polymer. More surprisingly, the difference of the
initial coating has a long-lasting effect on the degradation/
elimination of FeOx NPs, which persisted longer in spleen and
liver (more than one year), when coated with the amphiphilic
polymer. Regardless of the NPs, the elimination of magnetic iron
was almost complete in liver after a few months, while 10 to 30%
of the initial amount of magnetic iron still persisted in spleen six
months after administration. It is worth noting that the total
uptake of NPs is much higher in liver than in spleen (15 to 80%
of the injected dose in liver depending on NPs versus 2 to 6% in
spleen), but the concentration per gram of organ is larger in the
spleen. Thereby, the degradative capacity of the organ could be
saturated by a high local concentration of the material in the
spleen.
Apart from MRI, the in vivo degradation of FeOx NPs can be
also followed via radioactive labeling. The core material, i.e.,
the inorganic core of the FeOx NPs can be labeled either during
the synthesis or by neutron activation of the already synthe-
sized material. Recently, a fast, gentle, and quasi on-demand
method for post-synthetic labeling of monodisperse iron oxide
cores with 59Fe has been developed, which allows for studying
the distribution and metabolism of these cores in detail.86 After
intravenous injection in mice, the fate of FeOx NPs was studied,
cf. Fig. 3. After a lag phase of 3–7 days, 59Fe from the administered
FeOx NPs appeared in the hemoglobin of newly formed erythrocytes,
indicating the intracellular degradation of the FeOx NPs.
59Fe was
released from the cores and channeled into the physiological
transport ways for iron. However, a substantial part of the label
from the NPs was obviously retained in organs and tissues, probably
also indicating storage of intact or only partially degraded FeOx NPs,
presumably in cells other than macrophages.
It should be noted that the so-called 59Fe-erythrocyte incor-
poration rate (59Fe-EI) is a long-known and very unique parameter
for following the in vivo processing of iron from any given
iron supplement, including NPs. This has been monitored by
59Fe-labeled dextran or carboxydextran coated FeOx NPs used as
MRI contrast agents (Endorems, Resovists), during studies
involved in the registration procedure.164,165 The information
obtained from 59Fe-EI in living animals is whether iron is
released from the core of a NP at all, to what extent, and at
which time scale. In comparison to a test substance (e.g., ionic
Fe-salt), the degradation of a given FeOx core and the incorporation
of released iron in erythrocytes can be quantified. This technique, if
available, is an optimal complement to EPR, which quantifies the
persistent FeOx core through its magnetic properties and to multi-
scale imaging techniques including TEM in ex vivo samples, which
can give more insights into the mechanisms of uptake and
intracellular processing. However, without a reliable quantification
technique, these techniques always lack the information about how
relevant the collected data is for the studied in vivo system. Highly
fluorescent QDs with the same surface modification as FeOx NPs
can be alternatively used, to follow the cellular distribution and
uptake kinetics in vivo with intra-vital fluorescence microscopy.
This technique shows for example the special role of vascular
endothelial cells in the liver or outside the liver for the uptake of
different NPs.166
Together with the quantification at the organ level (i.e., the
recording of biodistributions), following inorganic cores at
the nanoscale in biological environments, is essential for
evaluating the degree of degradation of the nanostructures over
time and possibly, demonstrating the recycling of degradation
products in proteins. In this regard, the multi-functionalities of
TEM are of great interest because on the one hand, analytical
methods (energy dispersive X-ray (EDX) and electron energy
loss spectroscopies) allow studying the local biodistribution of
exogenous materials (from cellular up to the single NP or
protein levels) and on the other hand, high-resolution imaging
techniques provide the unique opportunity to probe the
atomic-structure of NP cores in the organism. Although the
morphological degradation of polydisperse 7–8 nm spherical
FeOx NPs is difficult to ascertain in vivo, FeOx nanocubes and
gold/iron oxide heterostructures show evident features of ero-
sion in the liver and spleen seven days after administration, cf.
Fig. 6. This is particularly conclusive for heterostructures,
because iron oxide crystals degrade around the gold cores,
leaving the less reactive gold remnants as long-lived witnesses
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of iron oxide dissolution in lysosomes. Nanoscale observations
also show that FeOx NPs become increasingly surrounded by
monodisperse (6 nm) iron-storing ferritin proteins, which are
rich in iron, but present different atomic structures than the
NPs and can thus be identified by high resolution TEM (Fig. 6,
day (D)14).50,110,163 The presence of ferritins proximally to FeOx
NPs suggests that iron released from degraded FeOx NPs could
be locally transferred to endogenous ferritins through a process
regulated by iron homeostasis.167 Consistently, an increase of
non-magnetic iron in spleens was observed, confirming the
local transformation of superparamagnetic FeOx NPs into non-
magnetic iron species. Such a scenario has a perfect plot: the
cell firstly confines the NPs within the lysosomes, where iron
remains bound in crystals until the proteins are synthesized
and recruited in the vicinity of NPs. Secondarily, in order to
allow a close approach of endogenous proteins, which tightly
and safely unload the iron cargo, while avoiding the cell
deleterious Fenton’s reaction, the cell progressively isolates
the NPs within the lysosomes, as observed by TEM.163 If
confirmed, the mechanisms of metal transfer from NPs to
endogenous proteins would exemplify a quintessential process
in which biomolecules and homeostasis regulate the local
degradation of NPs and recycle their by-products.
An advanced NP design could allow for a new generation of
inorganic NPs with controlled degradability of the inorganic
cores. For screening the factors that impact the lifecycle of NPs
in the body, one could track the aging of single cores in a
medium that mimics some features of the lysosomal environ-
ment, i.e., acidic pH (4.7), and the presence of iron chela-
tors,109,168 cf. Fig. 7. Consistent with in vivo observations, the
surface coating raises a more or less efficient shield to the effect
of the microenvironment and clearly governs the kinetics of
FeOx NP dissolution. At the single NP level, the areas of FeOx
NPs with less dense polymer coverage (e.g., the vertex of
nanocubes) are the most prone to degradation,163 cf. Fig. 8.
In addition to the above mentioned argument of the increased
surface-to-volume ratio present at edges, the degradation may
be sterically facilitated at these positions. As observed in vivo
for gold/iron oxide dimers, the hydrophilic PEG coating is less
effective in retarding the FeOx NP degradation than a double
chain amphiphilic polymer.50 In the case of Ag NPs, this effect
has not been observed in the same way.107
Fig. 6 Intralysosomal degradation of FeOx nanospheres, nanocubes and gold/FeOx heterostructures in murine splenic macrophages. At day 1 (D1) post-
injection, FeOx NPs are concentrated within lysosomes of macrophages. After one week (D7), a fair share of NPs arranges on the margins of lysosomes or
appears to be more isolated. Red arrows point to NP-adjacent to monodisperse iron-rich ferritin proteins. Some parts of gold/FeOx heterostructures
have been locally degraded leaving gold remnants (yellow arrows). Scanning transmission electron microscopy (STEM) – high-angle annular dark field
(HAADF) and elemental nanoanalysis by STEM-EDX confirm the partial or total disappearance of iron oxidesurrounding the resilient gold core. The Fourier
transformation (FT) of the degraded and resilient nanocubes at day 14 (D14, white square on the high resolution TEM micrograph) shows that nanocubes
maintain their initial lattice structure (spinel inverse or vacancy-ordered g-Fe2O3 structures). The FT of the ferritin protein core (red square) shows a
hematite structure, suggesting local transfer of iron from degraded NPs to the storage protein. An image adapted from a previously published
work.50,110,163
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Concerning NP geometry, the NP architecture also appears
to be a major factor that impacts the NP bio-persistence.
Multicore flower-shaped FeOx NPs, formed by the coalescence
of magnetically oriented iron oxide seeds, rapidly disintegrate
in lysosome-like medium, losing the outstanding properties
that they had owing to their cooperative structure.169 Impor-
tantly, the junctions in the multicore structures are the most
vulnerable sites. Apart from organic coatings, the association of
different materials allows for modulating the biopersistence of
NPs. For example, the disintegration of multicore FeOx nano-
flowers is more or less delayed when they are covered by a layer
of gold, depending on the thickness and porosity of the gold
shell.169 In a general manner, the degradation process of
inorganic cores is a step-by-step corrosion governed by surface
reaction mechanisms. Therefore, the efficiency of organic or
inorganic engineered coatings relies on their ability to prevent
the access of the cellular medium to the core surfaces. In vivo,
the 5 nm gold seeds associated with iron oxide spheres
Fig. 7 Progressive erosion of different FeOx NPs in lysosome-like medium. An image adopted from a previously published work.
50,163,169
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persisted much longer than the iron oxide crystals in splenic
and hepatic macrophages, but also showed reorganization (as
chains and assemblies) as well as degradation into smaller
structures one year after injection, once the iron oxide part had
been dissolved, cf. Fig. 6.50 Importantly, the size diminution of
poorly reactive NPs could enable size-dependent elimination
processes such as renal clearance, which could not occur in the
case of originally injected NPs. In addition, the variation in the
state of aggregation of the NPs in the lysosomes also plays an
important role in the possibility of degradation and clearance.
The way by which NPs could be excreted from macrophages or
translocated and cleared in other organs is another issue. It has
been shown recently that macrophages, endothelial cells or
mesenchymal stem cells that have first internalized FeOx
NPs170,171 Au NPs, QDs,172 or CNTs,173 can expulse NPs in the
extracellular medium within microvesicles when the cells are
stressed by starvation. Microvesicles are constitutively released
by virtually all cell types in body fluids and are considered as
potent vectors of intercellular communication in vivo. Such
vesicles can spread NPs across the body and transfer these
nanomaterials to distal cells. This propagation process,
mediated by underestimated vectors of NP dissemination,
additionally increases the importance of the in vivo fate of
NPs. Despite the non-ambiguous local degradation processes of
Fig. 8 Protective role of coating on NP degradation. (A) Carbon mapping obtained by energy filtered TEM (EFTEM) evidences the uneven coverage of
the amphiphilic polymer layer surrounding the cubes. White arrows point to polymer-poor regions where the degradation begins. An image adapted
from Lartigue et al.163 (B) Step-by-step degradation of nanocubes showing faster degradation in zones with poor polymer coating (black arrows) and the
protective effect of dense coating areas (blue arrows). (C) The coverage of multicore FeOx NPs with a 3 nm gold layer (iron featured in red and gold in
green on the Bragg filtered high-resolution micrograph on the left) protects the NPs from degradation. The EDX quantitative measurement of the Fe/Au
ratio shows that the thickest gold layer efficiently delays NP degradation and iron release in lysosome-like medium.
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NPs, it must be noted that a few resilient intact NPs could be
observed even one year after injection, regardless of the NP nature,
even in the case of highly biodegradable iron oxide. As observed
in vitro during single NP tracking, evidence shows that the degrada-
tion process is a non-linear and uneven process, which integrally
dissolves some NPs, while other particles remain unmodified. The
exact mechanisms of degradation, enzymatic attack and involvement
of cell metabolism in such a process still remain open questions.
Ideally the design of complex nanostructures should help modulat-
ing both the time frame of NP activity and the duration of degrada-
tion/excretion processes. Interestingly, the recent advances of TEM in
liquid environments could also help contemplating nanomaterials at
the nanoscale within biological environments, with the possibility of
observing the interaction between NPs and wet-cell cultures in situ
with unprecedented resolution.174,175 In addition, TEM in liquid
media opens many avenues for studying oxidative transformations
of NMs, by directly observing the effects of reactive-oxygen-species
(ROS) created by the electron beam by radiolysis processes, on the
atomic structure of NMs. As oxidative stress plays a critical role in the
cellular processing of NMs,176 such dynamic nanoscale investiga-
tions allow recapitulating the ROS-induced aging of NMs in cellular
media. For example, the in situ monitoring of CNT degradation
induced by hydroxyl radicals provided a mechanistic understanding
of the stigmata of degradation observed on nanotubes after aging
into macrophages.177
The examples listed in this review clearly demonstrate that
inorganic NP cores can be degraded in vivo. While this conclusion is
commonly reached in the literature for different materials,105 such
as Ag, FeOx, ZnO, the discussion about degradation of other
materials, such as Au, has just begun. While some cores degrade,
the exact mechanisms of degradation have not been fully under-
stood yet. Can NPs be completely dissolved and how these products
are excreted from the body? For NPs made of ‘‘inert’’ materials such
as Au, what are the detailed mechanisms of intracellular gold
dissolution? What is the role of the PC in core degradation, following
the observation that the PC changes over time, in particular after
NP internalization in lysosomes,118 and what is the role of intra-
lysosomal proteins? In case NP concentrations in one organ are
reduced over time, how to distinguish between translocation of
intact NPs (with or without coating) from organs where local
degradation occurs? If degradation happens, are the byproducts less
toxic than the original non-reactive persistent NPs? Does degrada-
tion depend on NP concentration, i.e., will lysosome overloaded with
NPs lead to impairment or acceleration of the degradative capacity of
cells and autophagy? Importantly, corroborating nanoscale informa-
tion (e.g., by TEM) with tissue level investigations (e.g., by ICP-MS,
magnetic and optical techniques) and biological studies (genetic and
proteomic techniques) is a cornerstone for addressing the many
open questions on the degradation of NP cores.
Conclusions
As interactions of NPs with their environments are dominated by
their surface and in this way by their engineered surface coating
together with adsorbed biomolecules, the biodistribution and
fate of NPs need to be correlated to their physicochemical
properties as well as their biocoating. While the physicochemical
properties and biocoating of NPs can be measured in different
biological fluids, there are only few appropriate techniques to
(kinetically) determine NPs in vivo and evaluate their evolution
over time through their route in the body. The most drastic
change in NP properties may involve in vivo degradation, and in
this way the fate of all NP components – the inorganic core,
the engineered surface coating, and the adsorbed biological
molecules – need to be analyzed. Assessing biodistribution and
clearance would involve multiple labeling strategies, in which all
different components can be traced and analyzed separately.
There is increasing experimental evidence that all of these
compounds may degrade in vivo. Thus, the hybrid nature of
NPs eventually transforms when they lose their integrity during their
voyage through the human body. While detailed extracorporeal NP
characterization provides information on the products we put ‘‘in’’
and take ‘‘out’’ of the body, the intracorporeal processes are still
shrouded in mystery.
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3, 2461.
116 O. Lunov, T. Syrovets, C. Rocker, K. Tron, G. Nienhaus,
V. Rasche, V. Mailander, K. Landfester and T. Simmet,
Biomaterials, 2010, 31, 9015.
117 K. Bose, M. Koch, C. Cavelius, A. K. Kiemer and
A. Kraegeloh, Part. Part. Syst. Charact., 2014, 31, 439.
118 M. Chanana, P. Rivera Gil, M. A. Correa-Duarte, W. J. Parak
and L. M. Liz-Marzán, Angew. Chem., Int. Ed., 2013,
52, 4179.
119 E. Casals, T. Pfaller, A. Duschl, G. J. Oostingh and
V. F. Puntes, ACS Nano, 2010, 4, 3623.
120 Z. Ali, A. Z. Abbasi, F. Zhang, P. Arosio, A. Lascialfari,
M. F. Casula, A. Wenk, W. Kreyling, R. Plapper, M. Seidel,
R. Niessner, J. Knoll, A. Seubert and W. J. Parak, Anal.
Chem., 2011, 83, 2877.
121 W. G. Kreyling, S. Hirn, W. Müller, C. Schleh, A. Wenk,
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